Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2024-03-21 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2024-03-21 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 18, 2024, reporting the entry into a material definitive agreement related to an underwritten public offering of common stock and pre-funded warrants. It details the terms of the offering, underwriting agreement, use of proceeds, and includes exhibits such as the underwriting agreement and legal opinion. The content focuses on a capital raising event and financing activities, not on financial results, management changes, or other report types. The document length is about 9,900 characters, which is substantive and contains detailed information about the financing transaction. Therefore, this filing fits the category of Capital/Financing Update (CAP).
2024-03-20 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically a public offering of common stock and pre-funded warrants. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and legal matters. This type of document is a capital markets filing related to fundraising and issuance of securities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing. Confidence is high due to clear identification of the document type and content.
2024-03-20 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of common stock and pre-funded warrants. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and legal matters. The document is clearly a registration and offering document for capital raising purposes, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update filings, which cover company fundraising and financing activities.
2024-03-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 14, 2024. It announces that the FDA has granted accelerated approval for a drug, Rezdiffra, and includes a press release and a corporate presentation as exhibits. The document does not contain detailed financial statements or comprehensive financial analysis but rather provides a regulatory update and company announcement. The presence of a corporate presentation attached suggests investor communication but the primary purpose is to disclose a material event (FDA approval). This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit the other more specific categories such as Earnings Release, Annual Report, or Capital Update. The document length is about 4700 characters, which is short and mainly an announcement rather than a full report or detailed presentation. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-03-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the appointment of a new Chief Financial Officer and the departure of other senior officers, including details about their compensation and severance arrangements. There are no financial statements or detailed financial results presented. The primary subject is changes in senior management and board-related personnel announcements. Therefore, this document fits the category of Board/Management Information (MANG). The document length and detail support a confident classification as MANG rather than a brief announcement or regulatory filing.
2024-02-28 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.